IL10 and acute myeloid leukemia: Treatment with an FLT3 inhibitor, midostaurin, showed a significant decrease in the Treg population, reduction in the FOX3p mRNA expression in AML cells, and reduction in IL-10 levels, indicating a role for IL-10 as a potential biomarker for AML cancer treatment [99].